Subject(s)
Cadaver , Kidney Transplantation/pathology , Kidney Tubules/pathology , Living Donors , Postoperative Complications/pathology , Acidosis/epidemiology , Child , Child, Preschool , Creatinine/blood , Drug Therapy, Combination , Female , Humans , Hypokalemia/epidemiology , Immunosuppressive Agents/therapeutic use , Infant , Kidney Transplantation/adverse effects , Kidney Transplantation/physiology , Magnesium Deficiency/epidemiology , Male , Phosphates/metabolism , Prospective Studies , Urination/physiologyABSTRACT
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.
